Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: XGN

Exagen Inc.

Healthcare | Medical - Diagnostics & Research

No licensed closing price on file for XGN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.82

Exagen Inc. (NASDAQ: XGN) is a diagnostics and research company. Figures from SEC EDGAR; updated 2026-10-20 09:48 UTC.

What Exagen Inc. does

Exagen is a medical technology company that designs, develops, and commercializes diagnostic testing products under the AVISE brand for rheumatic and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The company's flagship product, AVISE CTD, launched in 2012, enables differential diagnosis of connective tissue diseases and accounts for the vast majority of company revenue. In 2025, Exagen added eight new biomarkers to AVISE CTD to enhance its clinical utility.

Summarized from Exagen Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.82
Debt/equity1.87

Revenue, margins & earnings

FY2021: net loss $27M on revenue $48M$48MFY2021FY2022: net loss $47M on revenue $46M$46MFY2022FY2023: net loss $24M on revenue $53M$53MFY2023FY2024: net loss $15M on revenue $56M$56MFY2024FY2025: net loss $20M on revenue $67M$67MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-02
  • 2026-09-02Chief Financial OfficerAward1,571$4.7K
  • 2026-09-02Chief Financial OfficerSale-20,614$148.8K
  • 2026-08-24DirectorStock Option(right to buy)Award37,500—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →
No qualifying company news in the archive. Full tape in the platform →

Questions this page answers

What does Exagen Inc. do?

Exagen is a medical technology company that designs, develops, and commercializes diagnostic testing products under the AVISE brand for rheumatic and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis.

When did XGN last file with the SEC?

Exagen Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-09. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:48 UTC. This page is also available as JSON at /api/data?ticker=XGN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for XGN and 5,000+ tickers.

Create a free account — keep XGN
For your agent
GET /api/data?ticker=XGN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt